American Vanguard (AVJ) AI Stock Analysis

American Vanguard

(Frankfurt:AVJ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Specialty Segment GrowthSpecialty growth provides a durable counterweight to weaker agricultural demand because it reflects expansion across multiple end markets, including OHP biological solutions and TER. Continued performance in this segment can diversify revenue and support the company’s competitive position over the next several quarters.

Negative Factors

Recurring LossesPersistent net losses despite gross margin near 29% show that the company has not yet converted its product revenue into durable shareholder returns. Continued losses can erode equity, constrain reinvestment, and make future improvements dependent on successful cost reduction and operating recovery.

American Vanguard (AVJ) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 32.45M
Dividend Yield: ―
Average Volume (3M): 830
Price to Earnings (P/E): -0.6
Beta (1Y): 1.25
Revenue Growth: -10.16%
EPS Growth: 60.12%
Country: Germany
Employees: 739
Sector: Basic Materials
Sector Strength: 61
Industry: Agricultural Inputs

American Vanguard Business Overview & Revenue Model

Company Description

American Vanguard Corporation, through its various subsidiaries, develops, manufactures, and markets a diverse portfolio of specialized chemicals for agricultural, commercial, and consumer applications across the United States and internationally. Th...

American Vanguard Earnings Call Summary

Earnings Call Date:Aug 09, 2026(Q2-2026)|% Change Since:-56.14%|Next Earnings Date:Nov 09, 2026

Earnings Call SentimentNeutral

The call presents a mixed picture: significant operational progress (H1 gross margin improvement, >20% YTD adjusted EBITDA growth, specialty segment strength, R&D investment and announced cost savings) and clear strategic targets for 2026–2028. However, Q2 was notably weaker with a meaningful revenue decline, a steep drop in quarterly adjusted EBITDA, freight-driven margin headwinds, international softness, lower cash and higher net debt. Management emphasizes control of costs, pricing actions, and near-term initiatives to improve operating leverage and expects full-year targets to be met, which tempers the near-term negatives.

Positive Updates

US Outperformance and Sales Growth (H1)

US sales up 6% for the first half of FY26; US crop sales up 5% year-to-date. Company cites outperforming peers in combined US markets despite weak broader conditions.

Negative Updates

Quarterly Revenue Decline

Total sales in Q2 FY26 were $117 million versus $129 million in Q2 FY25, a decline of ~9.3% (management characterized overall quarterly net sales decline as ~10%). First half sales were $240 million, down ~2% from $245 million a year ago.

Company Guidance

Management reiterated 2026 guidance of $44–$48 million of adjusted EBITDA on $530–$550 million of sales, and said it expects to reach an annualized run rate north of $600 million by the back half of 2028 (about 20% above 2025) with a goal of double‑digit EBITDA margins; near‑term actions include LA plant rationalization to save at least $4 million annualized and pricing to recover freight headwinds (~$2.2M, ~90 bps YTD). Key reported metrics: Q2 sales $117M (vs. $129M a year ago), H1 sales $240M (down ~2% YoY), Q2 adjusted EBITDA $0.6M (vs. $11M prior) while H1 adjusted EBITDA rose to $17M (+>20% YoY), H1 gross margin improved 100 bps to 30% (Q2 GM 30% vs. 31% prior). Business mix and geography: US sales +6% H1 (US crop +5% H1, specialty +10% H1; specialty +11% in Q2), international sales -18% in Q2 and -13% H1; inventories $181M (vs. $191M prior year), cash $43.9M quarter‑end, total debt ~$267.6M and net debt ~$224.7M, and R&D investment up 12% YoY with a target of 50 new product launches over five years to drive $100M of annualized revenue by 2030.

American Vanguard Risk Analysis

American Vanguard disclosed 28 risk factors in its most recent earnings report. American Vanguard reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks

1.The development of Agentic AI tools may overtake the efficacy of available cybersecurity defense tools and, as such, could put the Company's computing systems at risk.Q2, 2026

2.The Company's primary synthesis factories are dependent upon the continued provision of shared services from competitors.Q2, 2026

3.The war between the US and Iran coupled with instability among other nations within the Middle East may have an adverse effect upon the agricultural economy in general and the Company's financial performance in particular.Q2, 2026

American Vanguard Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

DE:AVJ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UAN	75Outperform	$1.34B	8.36	51.56%	11.42%	17.47%	82.16%
IPI	73Outperform	$424.96M	15.81	5.27%	―	4.20%	―
Sector *	61Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
BHST	52Neutral	$37.63M	-3.07	-58.30%	―	17.50%	24.63%
BIOX	34Underperform	$13.15M	-0.06	-216.09%	―	-26.10%	14.85%

* Basic Materials Sector Average

Performance Comparison

DE:AVJ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:AVJ	American Vanguard Corporation	0.91	-2.78	-75.39%
UAN	CVR Partners LP	126.76	39.83	45.81%
IPI	Intrepid Potash Inc	31.58	5.30	20.17%
BHST	Bioharvest Sciences, Inc.	1.66	-7.59	-82.05%
BIOX	Bioceres Crop Solutions	0.21	-1.65	-88.82%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

American Vanguard AI Stock Analysis